Sermorelin has a well-established safety profile from its former FDA approval history. Common side effects include injection site reactions, flushing, and headache. It was voluntarily withdrawn from the market for commercial reasons, not safety concerns. Because it preserves pituitary feedback, it is considered less likely to cause GH-related side effects compared to direct GH injection.

How is it different from HGH injections?

Sermorelin stimulates your pituitary to produce its own growth hormone in a natural pulsatile pattern. HGH injections bypass the pituitary entirely and deliver a flat dose of synthetic growth hormone. Sermorelin preserves the body's natural feedback loop, while HGH can suppress your body's own GH production.

Sermorelin was formerly FDA-approved in 1997 under the brand name Geref for diagnosing and treating growth hormone deficiency in children. It was voluntarily withdrawn from the commercial market in 2008 for business reasons. It is now available through compounding pharmacies with a physician prescription.

How long before I notice effects?

GH elevation occurs within minutes of injection. Improved sleep quality is often reported within the first few weeks. Body composition changes, if any, typically require 3-6 months of sustained use.

Can it be combined with other peptides?

Sermorelin is sometimes combined with Ipamorelin or other GH secretagogues to target complementary pathways. This is pharmacologically rational but no controlled studies have demonstrated that combinations are superior to sermorelin alone.

What mechanism of action has been identified?

One of the few GH-releasing peptides to achieve FDA approval, validating the GHRH receptor mechanism for stimulating endogenous GH production. The approval (as Geref) for pediatric GH deficiency provided regulatory-level evidence that GHRH analogs can reliably stimulate GH secretion

What does the research show about: Voluntarily withdrawn from market in 2008 for commercial reasons, not safety, cr?

Voluntarily withdrawn from market in 2008 for commercial reasons, not safety, creating an unusual formerly approved regulatory status. This distinction matters: sermorelin's withdrawal was a business decision, not a safety signal. It retains a more favorable regulatory history than compounds that never achieved approval

What does the research show about: Preserves physiological GH pulsatility and hypothalamic-pituitary feedback, unli?

Preserves physiological GH pulsatility and hypothalamic-pituitary feedback, unlike exogenous GH which suppresses endogenous production. This is the primary theoretical advantage of GHRH analogs over direct GH replacement, though whether this translates to better long-term outcomes has not been confirmed

What does the research show about: Human studies confirm dose-dependent GH and IGF-1 increases, improved lean body ?

Human studies confirm dose-dependent GH and IGF-1 increases, improved lean body mass, and enhanced slow-wave sleep. These are real human outcomes, though most come from GH-deficient populations rather than healthy adults seeking optimization

Have any randomized controlled human trials been completed?

Adult anti-aging and body composition claims are widely promoted but incompletely supported by controlled trial data. The gap between clinical use (pediatric GH deficiency) and popular use (adult anti-aging) is significant. Most adult claims extrapolate from deficiency data

reviewed april 2026|next review october 2026|88 physicians psi has verified|328 published studies

Sermorelin

Sermorelin is a 29-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH) that was FDA-approved as Geref from 1997 until voluntarily withdrawn in 2008, making it one of the few peptides to have held and then lost FDA approval.

Evidence landscape: 328 published studies

328 published items: 20 human studies and 174 animal studies. The human evidence base includes controlled trials from the FDA-approved period (1997-2008) and subsequent clinical research.

20 Human
174 Animal
6 Reviews
128 Other research

Not currently FDA-approved. A doctor can have it prepared through a specialty pharmacy, where a licensed pharmacist prepares a medicine from ingredients for an individual patient. This is legal and routine in U.S. medicine. It was FDA-approved as Geref from 1997 to 2008; the approval was voluntarily withdrawn for commercial reasons, not safety or efficacy concerns.

Controlled human trials during the FDA-approved period established that sermorelin reliably stimulates growth hormone release in a physiological pulsatile pattern. The evidence base for the original indication (pediatric growth hormone deficiency) is substantially stronger than for most research peptides.

Most current use is for an adult indication the FDA has not formally approved, which is growth hormone optimization. Controlled trials for those uses are limited. The magnitude of clinical benefit compared with newer growth hormone secretagogues is not established.

PSI Assessment

Between 1997 and 2008, sermorelin was an FDA-approved medication sold as Geref for pediatric growth hormone deficiency. The manufacturer voluntarily withdrew it from the market for commercial reasons. The safety and efficacy evidence that supported the approval did not change. Today it is available through compounding pharmacies, where a licensed pharmacist prepares a medicine from ingredients for an individual patient with a doctor's prescription, and most use is for adult growth hormone optimization, an indication the original FDA approval never covered and for which controlled outcome trials are limited.

Held FDA approval for 11 years. Withdrawn for commercial reasons. The safety and efficacy evidence that supported approval did not change.

The mechanism is clean: sermorelin stimulates the pituitary gland to release growth hormone in a natural pulsatile pattern through the same receptor the body's own GHRH uses. This preserves the feedback axis that direct growth hormone injection bypasses. The open question is whether the growth hormone increase from sermorelin is large enough to produce the clinical outcomes adults commonly seek it for, and how it compares to newer secretagogues like tesamorelin and CJC-1295.

What the evidence supports

Controlled trials during the FDA-approved period established that sermorelin stimulates physiological growth hormone release. Diagnostic use for growth hormone deficiency is validated. The safety record across 11 years of FDA approval and subsequent compounding use is clean.

What is not yet established

Whether sermorelin produces clinically meaningful outcomes for the adult uses most patients seek it for: body composition, sleep quality, recovery. How it compares to newer secretagogues (tesamorelin, CJC-1295, ipamorelin) in controlled trials.

Research Evidence

The findings below cover what the FDA-approved era established and where the evidence thins for current adult use.

Evidence by condition

Evidence dimensions across sermorelin's clinical and investigational uses. The FDA-approved indication (pediatric GH deficiency) and diagnostic use have the deepest evidence. Adult optimization uses have mechanism and animal support but limited controlled human data.

Condition	Mechanism	Animal evidence	Human evidence	Replication
Growth Hormone Deficiency (pediatric)
GH Reserve Diagnostic Testing
Adult Body Composition (non-approved use)
Sleep Quality (non-approved use)
Adult Anti-Aging (non-approved use)

Controlled trials during the FDA-approved period established that sermorelin reliably stimulates growth hormone release when pituitary function is intact, with a dose-dependent response.

This was established with the FDA-grade trial data that supported the Geref approval. Whether the magnitude of the growth hormone increase translates into the downstream clinical outcomes adults commonly seek is a different question, addressed below.

Most current sermorelin prescribing is for adult body composition, sleep quality, and recovery, not the pediatric growth hormone deficiency that the original FDA approval covered. Controlled trials for these specific adult outcome endpoints are limited.

Adult prescribing through compounding pharmacies, where a licensed pharmacist prepares the medicine for an individual patient, has been extensive for more than a decade. The mechanism supports these applications. The controlled-trial evidence for outcome measures like body composition change, sleep quality, or recovery is sparser than the volume of prescribing would suggest.

Sermorelin is used clinically as a diagnostic agent for evaluating growth hormone reserve in patients with suspected pituitary dysfunction. This use is validated by multiple controlled studies.

Sermorelin plus arginine stimulation is an established test for adult growth hormone deficiency. This is a well-validated use case that survives despite the loss of the therapeutic approval.

20 Human|174 Animal|6 Reviews

View all 328 indexed studies

How Sermorelin Works

Sermorelin is a 29-amino-acid synthetic peptide, which means it is a short chain of building blocks that normally make up proteins. It is the first 29 amino acids of growth hormone-releasing hormone, the natural signal your brain sends to your pituitary gland to release growth hormone.

Sermorelin is essentially a shorter version of the signal your brain sends to your pituitary gland to release growth hormone. It works with your body's own system rather than bypassing it, which is why it preserves the natural pulsatile pattern of GH release.

For a more detailed view of the biology, here is what researchers have observed at the molecular level.

Sermorelin corresponds to the bioactive N-terminal fragment of the body's own GHRH(1-44) protein. It binds the GHRH receptor on anterior pituitary somatotrophs, activating adenylyl cyclase via Gs-protein coupling, which increases intracellular cAMP and triggers GH gene transcription and secretion. The short half-life (approximately 10 to 20 minutes) produces acute GH pulses rather than sustained elevation, preserving the natural pulsatile pattern of pituitary function. This pharmacokinetic profile means effects depend on dosing frequency and timing, typically bedtime administration to align with the natural nocturnal GH surge. The compound appears to maintain or upregulate GHRH receptor sensitivity over time, in contrast to continuous GH administration which downregulates GH axis responsiveness.

What is Sermorelin being studied for?

Researchers are studying Sermorelin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Sermorelin overall. This means a compound can have human studies for one condition but only animal data for another.

Growth Hormone Deficiency (pediatric)

·Human Trials

Controlled trials during the FDA-approved period demonstrated sermorelin reliably stimulates growth hormone release and supports growth in children with GH deficiency. This was the basis for Geref's 1997 approval.

Limitations: Efficacy depends on intact pituitary function. Patients with severe pituitary damage may not respond. The current regulatory status (post-2008 withdrawal) limits U.S. access to pharmacy-prepared formulations.

GH Reserve Diagnostic Testing

·Human Trials

Sermorelin plus arginine stimulation testing is a validated method for evaluating growth hormone reserve in suspected pituitary dysfunction. This diagnostic use is supported by multiple controlled studies.

Limitations: Diagnostic, not therapeutic. Does not establish outcomes beyond the stimulation result itself.

Adult Body Composition (non-approved use)

·Animal Studies

Small human studies show trends toward increased lean mass and decreased body fat with sustained sermorelin use. Effects are modest compared to direct growth hormone administration.

Limitations: Most body composition data comes from GH-deficient populations. Whether healthy adults see meaningful changes is less clear. Large-scale outcome trials for adult use outside the approved indication are lacking.

Sleep Quality (non-approved use)

·Animal Studies

Some clinical research suggests improved deep sleep patterns with sermorelin use, consistent with the natural role of the nocturnal GH surge in sleep architecture.

Limitations: Sleep outcome data is limited. Most reports are small studies or subjective. Objective polysomnography data is sparse.

Adult Anti-Aging (non-approved use)

·Preclinical

Adult prescribing for anti-aging and longevity, which is a use the FDA has not formally approved, is widespread through specialty pharmacies that prepare a medicine from ingredients for an individual patient. The premise is that restoring the pulsatile GH pattern may offset age-related decline.

Limitations: No controlled outcome trials support anti-aging endpoints. The biological rationale is plausible but the clinical evidence for longevity or aging-biomarker outcomes does not exist at the trial level.

Safety and Regulatory Status

FDA Status: Not currently FDA-approved. Approved as Geref from 1997 to 2008; voluntarily withdrawn by the manufacturer for commercial reasons, not safety or efficacy failure.

U.S. access: A doctor can have sermorelin prepared through a specialty pharmacy, where a licensed pharmacist prepares a medicine from ingredients for an individual patient. This is legal and routine in U.S. medicine.

Clinical use: Prescribed by physicians for growth hormone optimization (a use the FDA has not formally approved) and for growth hormone reserve diagnostic testing. Also used in some international jurisdictions under different regulatory frameworks.

Sermorelin had a well-established safety profile during its FDA-approved period. The most common side effects were mild injection-site reactions, flushing, and headache. No significant organ toxicity was identified in clinical use.

Peptide Structure

Technical molecular data for researchers and clinicians.

Questions and Comparisons

Questions the evidence raises for a Sermorelin discussion.

Comparison and Related Research

Sermorelin is most often compared with other growth hormone secretagogues. The comparisons below outline how each differs in mechanism, evidence base, and regulatory status.

Head-to-head comparisons

Full research comparisons covering Sermorelin and another peptide side by side.

Sermorelin vs CJC-1295

Research-based comparison of sermorelin and CJC-1295 for growth hormone stimulation. Mechanism, pharmacokinetics, evidence levels, and clinical data compared side-by-side.

View full comparison

Sermorelin vs CJC-1295 No DAC (Mod GRF 1-29)

Evidence-based comparison of Sermorelin and CJC-1295 No DAC (Mod GRF 1-29). Pharmacokinetic similarity, branding clarity, regulatory history, and sourcing differences.

View full comparison

Sermorelin vs Ipamorelin

Sermorelin has a longer clinical history. Ipamorelin is more selective. Evidence-graded comparison for growth hormone optimization, mechanisms, safety, and study data.

View full comparison

Sermorelin vs MK-677 (Ibutamoren)

MK-677 is oral with more data but metabolic side effects. Sermorelin is injectable with a longer safety record. Evidence-graded GH optimization comparison.

View full comparison

Related compounds

Tesamorelin CJC-1295 CJC-1295 No DAC Ipamorelin Hexarelin

Frequently Asked Questions

References

Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.

1.Comprehensive clinical review of sermorelin covering diagnostic and therapeutic use in pediatric growth hormone deficiency, the indication for which it held FDA approval.Prakash A, Goa KL, 1999 in BioDrugs. View on PubMed
2.Early clinical trial demonstrating that sermorelin stimulates growth hormone release in children with growth hormone deficiency, supporting its later FDA approval.Walker RF et al., 1990 in J Pediatr. View on PubMed
3.Clinical study showing that nightly sermorelin injections increased growth hormone secretion in healthy elderly men without suppressing the endogenous GH axis.Vittone J et al., 1997 in Metabolism. View on PubMed
4.Diagnostic study using sermorelin plus arginine to evaluate growth hormone reserve in adult patients with pituitary tumors, illustrating the diagnostic use case.Aimaretti G et al., 2006 in J Clin Endocrinol Metab. View on PubMed
5.Quantitative analysis correlating growth hormone secretion patterns with final adult height, referencing GHRH stimulation data.Carel JC et al., 1999 in J Clin Endocrinol Metab. View on PubMed
6.Exploratory clinical observation evaluating sermorelin in patients with recurrent glioma, an off-label research direction distinct from its original GH-deficiency indication.Chen et al., 2021 in Clinical publication. View on PubMed
7.Clinical study in healthy young and older men demonstrating that GHRH analogs stimulate growth hormone release in both age groups, with implications for adult use.Khorram O et al., 2005 in J Clin Endocrinol Metab. View on PubMed
8.Foundational NEJM clinical trial showing that once-daily GHRH therapy accelerated growth in children with growth hormone deficiency, informing the FDA approval pathway.Thorner MO et al., 1988 in N Engl J Med. View on PubMed

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.